Merck, 372770-1MG, HBDDE

General description
A cell-permeable protein kinase C (PKC) inhibitor that selectively inhibits PKCα (IC₅₀ = 43 µM) and PKCγ (IC₅₀ = 50 µM) over PKCδ, βI, and βII isozymes in in vitro assays. Reported to induce apoptosis in rodent cerebellar granule neurons.
Protein kinase C (PKC) inhibitor. Selectively inhibits PKCα (IC₅₀ = 43 µM) and PKCγ (IC₅₀ = 50 µM) over PKCδ, βI and βII isozymes.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PKCα
Product does not compete with ATP.
Reversible: no
Target IC₅₀: 43 µM against PKCα
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Mathur, A., and Vallano, M.L. 2000. Biochem. Pharmacol.60, 809.
Kashiwada, Y., et al. 1994. J. Med. Chem. 37, 195.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)